Sumitomo Dainippon Pharma

Jul. 29, 2021 (PDF/972KB)Finances

Presentation Material（First Quarter Financial Results for FY2021）
Jul. 29, 2021 (PDF/420KB)Finances

Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2022
Jul. 29, 2021 (PDF/355KB)Finances

Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2022 [IFRS]
Jul. 20, 2021 (PDF/41KB)Products

Myovant Sciences Announces European Commission Approval for RYEQO for the Treatment of Women With Uterine Fibroids
Jun. 23, 2021 (PDF/221KB)Products

Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan

Other Notices

Jun. 30, 2021Others

Posted Factbook 2021
Jun. 24, 2021Corporate (PDF/103KB)

Sumitomo Dainippon Pharma Announces Release of Movie on Change of Company Name
May 26, 2021Corporate

Posted Notice of Convocation of the 201th Annual Shareholders' Meeting

IR Library

Movie on Change of Company Name

Change company name from April 2022
Company Introduction Movie

Continuing to challenge ourselves to support a healthy future for people
Research and Development

Aiming to create innovative pharmaceutical products
CSR

Targeting sustainable growth
Overseas Local Subsidiaries

Leading our global expansion
Frontier Business Website

Thinking BEYOND medication